Daily Derm Times: July 30, 2025

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Journal Digest: July 30, 2025

This review of the latest dermatologic studies includes insights into emerging terbinafine resistant trichophyton dermatophytosis, clinicodemographic features and usage of oral immunosuppressive agents in childhood and adolescent vitiligo, and more.

LEO Pharma’s Robert Spurr on Delgocitinib Cream’s Approval and the Future of Chronic Hand Eczema

Delgocitinib cream recently became the first FDA-approved treatment for chronic hand eczema. Robert Spurr of LEO Pharma shares insights into what it means for providers and patients.

New Phase 3 UP-AA Data Demonstrate Significant Improvement in SALT Score With Upadacitinib in Alopecia

AbbVie's upadacitinib showed promising results in treating severe alopecia areata, achieving significant hair regrowth in pivotal phase 3 trials.

Phase 2b Repibresib Study Falls Short of Key Goals

VYNE Therapeutics revealed phase 2b trial results for repibresib gel in nonsegmental vitiligo, missing key efficacy endpoints.

New Research Reveals PC111's Potential to Revolutionize Pemphigus and SJS/TEN Treatment

PC111, a novel therapy from Scinai, targets pemphigus vulgaris and SJS/TEN, offering rapid relief without immunosuppression.

Derm Dispatch: Navigating Industry, Health Care, and Career Transitions as a PA

Explore career transitions in healthcare as PAs Renata Block, MMS, PA-C, and Jessica Dell'Aquila, MS, PA-C, share insights on professional growth and evolving roles in dermatology.

SPD 2025: Bridging Research and Clinical Care

Deepti Gupta, MD, emphasized SPD's focus on delivering practical clinical insights, highlighting emerging research, and fostering meaningful professional connections